Overview

A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects

Status:
Not yet recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
Primary Objective is to evaluate the safety and efficacy of OT-101+Artemisinin when used in combination with standard of care (SoC) in hospitalized COVID 19 subjects versus SoC+ Artemisinin+Placebo.
Phase:
Phase 2
Details
Lead Sponsor:
Oncotelic Inc.
Treatments:
Artemisinin
Artemisinine
Artemisinins
Trabedersen